SkinBioTherapeutics (LON:SBTX) Shares Down 0.1% – Time to Sell?

SkinBioTherapeutics plc (LON:SBTXGet Free Report) shares were down 0.1% during mid-day trading on Tuesday . The stock traded as low as GBX 17.50 ($0.22) and last traded at GBX 17.73 ($0.22). Approximately 257,072 shares changed hands during mid-day trading, a decline of 42% from the average daily volume of 439,623 shares. The stock had previously closed at GBX 17.75 ($0.22).

SkinBioTherapeutics Price Performance

The firm has a market capitalization of £40.07 million, a P/E ratio of -886.25 and a beta of 2.01. The company has a quick ratio of 10.01, a current ratio of 6.57 and a debt-to-equity ratio of 2.66. The business’s 50-day simple moving average is GBX 17.06 and its 200 day simple moving average is GBX 14.20.

SkinBioTherapeutics (LON:SBTXGet Free Report) last posted its quarterly earnings results on Wednesday, December 4th. The company reported GBX (1.54) (($0.02)) EPS for the quarter.

SkinBioTherapeutics Company Profile

(Get Free Report)

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.

Featured Stories

Receive News & Ratings for SkinBioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SkinBioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.